Synergy Pharmaceuticals to Present at the Cantor Fitzgerald Healthcare Conference

NEW YORK--(BUSINESS WIRE)--

Synergy Pharmaceuticals Inc. SGYP today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 at 2:30 p.m. Eastern Time at Le Parker Meridien Hotel in New York City.

A live webcast of the presentation will be accessible through the Investor Relations section of the company's website at www.synergypharma.com. A replay of the webcast will be available on Synergy's website for 60 days.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of novel therapies for the treatment of gastrointestinal (GI) diseases and disorders. Synergy's proprietary platform technology is based on the naturally occurring human GI peptide, uroguanylin, a key regulator of normal GI physiology. Plecanatide is our first uroguanylin analogue currently in late-stage clinical development for chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide (SP-333) is our next-generation uroguanylin analogue presently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150630005269/en/